Global Information
회사소개 | 문의 | 비교리스트

인터류킨 12 수용체(IL12R) : 파이프라인 리뷰

Interleukin 12 Receptor (IL12R) - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 423718
페이지 정보 영문 47 Pages
가격
US $ 3,500 ₩ 4,258,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,516,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,774,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


인터류킨 12 수용체(IL12R) : 파이프라인 리뷰 Interleukin 12 Receptor (IL12R) - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 47 Pages

인터류킨 12 수용체(IL12R)를 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

인터류킨 12 수용체(IL12R) 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

파이프라인 제품 상황 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

치료제 평가

  • 단독치료 제품/병용요법 제품별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여기업

  • Eli Lilly and Company
  • Mallinckrodt Plc
  • Merck KGaA
  • Neumedicines Inc

약제 개요

  • Cellular Immunotherapy to Activate Interleukin-12 for Skin Cancer
  • edodekin alfa SR
  • LY-3232094
  • M-9241
  • NMIL-121

휴지 상태인 프로젝트

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

부록

도표

LSH 17.02.27

Summary:

Global Markets Direct's, 'Interleukin 12 Receptor (IL12R) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 12 Receptor (IL12R) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 12 Receptor (IL12R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 12 Receptor (IL12R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 12 Receptor (IL12R)
  • The report reviews Interleukin 12 Receptor (IL12R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 12 Receptor (IL12R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 12 Receptor (IL12R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 12 Receptor (IL12R) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 12 Receptor (IL12R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 12 Receptor (IL12R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 12 Receptor (IL12R) Overview
  • Therapeutics Development
    • Interleukin 12 Receptor (IL12R) - Products under Development by Stage of Development
    • Interleukin 12 Receptor (IL12R) - Products under Development by Therapy Area
    • Interleukin 12 Receptor (IL12R) - Products under Development by Indication
  • Interleukin 12 Receptor (IL12R) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Interleukin 12 Receptor (IL12R) - Products under Development by Companies
  • Interleukin 12 Receptor (IL12R) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 12 Receptor (IL12R) - Companies Involved in Therapeutics Development
    • Eli Lilly and Company
    • Mallinckrodt Plc
    • Merck KGaA
    • Neumedicines Inc
  • Interleukin 12 Receptor (IL12R) - Drug Profiles
    • Cellular Immunotherapy to Activate Interleukin-12 for Skin Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • edodekin alfa SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3232094 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-9241 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMIL-121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 12 Receptor (IL12R) - Dormant Projects
  • Interleukin 12 Receptor (IL12R) - Discontinued Products
  • Interleukin 12 Receptor (IL12R) - Featured News & Press Releases
    • Mar 02, 2015: Department of Defense Supports Neumedicines With Groundbreaking Grant for Surgical Site Infection Therapy
    • Apr 28, 2014: Phase I Clinical Study of Neumedicines' Interleukin-12 as a Treatment for Wound Healing and Infections Recommended for Funding by the U.S. Department of Defense
    • Apr 18, 2014: Neumedicines Publishes Clinical Data Demonstrating Safety and Hematopoietic and Immune Effects of HemaMax (rHuIL-12), a Radiation Medical Countermeasure
    • Apr 15, 2014: Neumedicines Announces Publication of Phase II-Equivalent Data Demonstrating the Survival Effect of HemaMax (rHuIL-12), a Radiation Medical Countermeasure
    • Jan 09, 2014: Neumedicines to Feature HemaMax Study Results in Presentation at Biotech Showcase Conference
    • Dec 13, 2013: Neumedicines Presents HemaMax Clinical Data at the ASH Conference
    • Jun 10, 2013: Neumedicines Receives $8.3m Award From BARDA For Continued Development Of HemaMax As Countermeasure To Acute Radiation Exposure
    • May 14, 2013: Neumedicines Receives BARDA Notification Of Intent To Exercise Contract Option To Continue Development Of HemaMax As Radiation Medical Countermeasure
    • Jan 25, 2013: Neumedicines Presents Data On HemaMax At BARDA And NIAID Sponsored Symposium
    • Jul 23, 2012: TherapyX Partners with Neumedicines
    • May 05, 2012: Neumedicines's HemaMax Demonstrates Unprecedented Survivability After Lethal Dose Of Radiation In Mice And Non-Human Primates
    • Mar 05, 2012: Neumedicines's HemaMax Demonstrates Positive Preclinical Results After Lethal Dose Of Radiation In Mice And Non-Human Primates
    • Sep 27, 2011: Neumedicines Wins US Federal Government Contract Up To $273m To Fund Late-Stage Development Of HemaMax
    • Jan 31, 2011: Neumedicines Receives Notice Of Allowance For Patent Covering Use Of HemaMax To Treat Chemotherapy-Induced Thrombocytopenia
    • Aug 12, 2010: Neumedicines Receives $2.5 Million From HHS/BARDA After Successful Non-Human Primate Studies to Further Advance HemaMax As a Radiation Countermeasure
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Eli Lilly and Company, H2 2016
  • Pipeline by Mallinckrodt Plc, H2 2016
  • Pipeline by Merck KGaA, H2 2016
  • Pipeline by Neumedicines Inc, H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top
전화 문의
F A Q